Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 134

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 8
Chunk 134
---
.2 %$27.2 Evomela26.5 20.0 %5.3 29.5 20.0 %5.9 Teriparatide injection(1)21.5 28.4 %6.1 24.3 26.7 %6.5 Rylaze 299.5 3.2 %9.5 309.4 3.3 %10.1 Filspari233.3 9.0 %21.0 82.2 9.0 %7.4 Vaxneuvance672.5 0.9 %6.0 636.9 0.6 %4.0 Ohtuvayre(2)310.0 2.0 %6.2 5.6 1.8 %0.1 Capvaxive477.5 1.3 %6.3 58.0 0.7 %0.4 Other294.5 2.1 %6.3 258.9 2.3 %5.9 Total$3,503.7 $91.8 $2,618.5 $67.5 

 (1) We receive tiered profit sharing of 25% on quarterly profits less than $3.75 million, 35% on quarterly profits greater than $3.75 million but less than $7.5 million and 40% on quarterly profits greater than $7.5 million. 

(2) Our royalty rate on Ohtuvayre is 3%, of which 2% is recognized in revenue from intangible royalty assets and the remaining 1% is accounted for as financial royalty asset. See detail in Note 5, Financial Royalty Assets, net.

Operating Costs and Expenses

(Dollars in thousands)Q3 2025% of RevenueQ3 2024% of RevenueYTD 2025% of RevenueYTD 2024% of RevenueCost of Captisol$3,801 $2,449 $11,557 $8,237 Amortization of intangibles8,097 8,258 24,612 24,701 Research and development21,019 5,675 77,671 17,000 General and administrative28